Delivery Order SPE2DB22D9367-SPE2DB25FSY80
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on June 2, 2025, with a ceiling value of $20,085.04. The contract calls for the delivery of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials, a long-acting local anesthetic used in surgical and medical settings. The award carries no set-aside designation and is scheduled for ultimate completion...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 27, 2025, for EXPAREL 266 mg/20 ml vials valued at $10,042.52. This firm fixed-price delivery order, which has a completion date of September 18, 2025, was issued without a set-aside designation. The award represents a single delivery order under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency valued at $4,873.76 for EXPAREL (liposomal bupivacaine) 133 mg/10 mL vials. The award, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $8,234.32 by the Defense Logistics Agency (DLA) for the supply of EXPAREL 266 mg/20 ml vials. The award, issued on May 20, 2025, with an ultimate completion date of June 11, 2025, operates under a firm fixed-price contract type with no set-aside designation. EXPAREL is a liposomal bupivacaine formulation used for prolonged local...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on August 11, 2025, by the Defense Logistics Agency (DLA) for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order, valued at $7,531.89 with an ultimate completion date of September 2, 2025, represents a task order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a $10,550.54 firm fixed-price delivery order on May 12, 2025, by the Defense Logistics Agency's Medical Supply Chain division for the supply of EXPAREL 133 mg/10 ml vials. The award carries an ultimate completion date of June 3, 2025, and does not utilize a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $5,021.26 for EXPAREL 1.3% 20ML (10 units) by the Defense Logistics Agency's Medical Supply Chain. The contract was awarded on July 31, 2025, with an ultimate completion date of the same day, and carries no set-aside designation. EXPAREL is a liposomal bupivacaine formulation used for local anesthesia and...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a $25,106.30 firm fixed-price delivery order by the Defense Logistics Agency on August 14, 2025, for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. The contract carries an ultimate completion date of September 5, 2025, and involves no set-aside designation. This delivery order represents a continuation of DMS Pharmaceutical Group's substantial role...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $30,127.56 on July 14, 2025, by the Defense Logistics Agency's Medical Supply Chain. The contract covers the supply of EXPAREL 266 mg/20 ml vials, a liposomal bupivacaine local anesthetic used in surgical and post-operative pain management. The delivery order is firm fixed price with an ultimate completion date of August 4, 2025, and...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a firm fixed-price delivery order valued at $37,659.45 for the supply of EXPAREL 266 mg/20 mL vials. The award, made on August 25, 2025, with an ultimate completion date of September 16, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency...
- SPE2DB22D9367Indefinite Delivery Contract
- SPE2DB22D9367-SPE2DB25FSY80Delivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency valued at $16,071.40 for EXPAREL 266 mg/20 ml vials. The contract, awarded on July 14, 2025, with an ultimate completion date of August 4, 2025, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion vehicle that enables the agency to procure a comprehensive range of pharmaceutical products supporting military health facility supply chains worldwide. EXPAREL is a liposomal bupivacaine local anesthetic used for infiltration and nerve blocks in surgical settings. This delivery order reflects DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical distribution network, leveraging its woman-owned small business status to compete effectively in Defense Logistics Agency procurement markets. The company's extensive portfolio with the DLA encompasses branded and generic prescription drugs, biologics, medical consumables, and specialty pharmaceutical products supporting Department of Defense healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.1k | 7/14/25 |